Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112123 · ClinicalTrials.gov registry record · Phase 1
Icariin to Prevent Corticosteroid-related Memory Changes
A Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02112123: Completed Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans, sponsored by University of Texas Southwestern Medical Center.
NCT02112123 is a Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02112123, a Phase 1 study of the Pharmacokinetic Profile of Icariin in Humans, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the pharmacokinetic properties of icariin, an active ingredient in the over-the-counter supplement, Horny Goat Weed.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Matching placebo
- DRUG Icariin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
What the finished NCT02112123 record still lists
NCT02112123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with the Pharmacokinetic Profile of Icariin in Humans appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.
NCT02112123 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02112123 about?
NCT02112123 is a clinical study titled "Icariin to Prevent Corticosteroid-related Memory Changes". The purpose of this study is to investigate the pharmacokinetic properties of icariin, an active ingredient in the over-the-counter supplement, Horny Goat Weed.
What is the current status of trial NCT02112123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-04. Estimated completion is 2016-12.
What conditions does trial NCT02112123 study?
This clinical trial studies the following conditions: the Pharmacokinetic Profile of Icariin in Humans.
What interventions are being tested in trial NCT02112123?
The interventions under investigation include: Matching placebo (DIETARY_SUPPLEMENT), Icariin (DRUG).
Who is sponsoring clinical trial NCT02112123?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112123 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02112123's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia